WHO: Prices, Costs, and Affordability of New Meds for HCV in 30 Countries - An Economic Analysis
Algolia Search

WHO: Prices, Costs, and Affordability of New Meds for HCV in 30 Countries - An Economic Analysis

New hepatitis C virus (HCV) medicines have markedly improved treatment efficacy and regimen tolerability. However, their high prices have limited access, prompting wide debate about fair and affordable prices. This study systematically compared the price and affordability of sofosbuvir and ledipasvir/sofosbuvir across 30 countries to assess affordability to health systems and patients.

Prices Costs and Affordability of New Meds for HCV in 30 Countries - Economic Analysis.pdf